Related Experiment Videos
Adjuvant therapy for gastric cancer
1Department of Gastrointestinal Oncology, St. Vincent's Comprehensive Cancer Center, New York, NY, USA.
Seminars in Oncology
|September 25, 2003
Summary
Adjuvant chemoradiation after gastric cancer resection significantly improves survival rates for patients with lymph node metastases. This combined treatment is now a standard of care, offering hope against recurrent cancer.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Complete resection is crucial for curative management of gastric adenocarcinoma.
- High recurrence (70-80%) and mortality rates exist for patients with lymph node metastases post-resection.
- Debate continues regarding the survival benefits of extensive (D2) versus less extensive lymph node dissection.
Purpose of the Study:
- To evaluate the efficacy of adjuvant chemoradiation in improving outcomes for resectable gastric cancer patients.
- To establish a new standard of care for gastric adenocarcinoma management post-surgery.
Main Methods:
- Analysis of a large United States Intergroup study (INT-0116) data.
- Comparison of outcomes between patients receiving standard care and those undergoing combined chemoradiation post-gastric resection.
Main Results:
- Combined chemoradiation significantly improved median time to relapse (30 vs. 19 months, P <.0001).
- Overall survival was notably enhanced with combined chemoradiation (35 vs. 28 months, P =.01).
Conclusions:
- Combined chemoradiation following gastric resection is an effective treatment strategy.
- This approach has become a standard of care for gastric cancer patients with lymph node metastases.
- Future research directions include neoadjuvant chemoradiation and targeted therapies.